Background. Jellyfi sh stings are a common occurrence among ocean goers worldwide with an estimated 150 million envenomations annually. Fatalities and hospitalizations occur annually, particularly in the Indo-Pacifi c regions. A new topical jellyfi sh sting inhibitor based on the mucous coating of the clown fi sh prevents 85% of jellyfi sh stings in laboratory settings. The fi eld effectiveness is unknown. The objective is to evaluate the fi eld effi cacy of the jellyfi sh sting inhibitor, Safe Sea ™ . Methods. A double-blind, randomized, placebo-controlled trial occurred at the Dry Tortugas National Park, FL, USA and Sapodilla Cayes, Belize. Participants were healthy volunteers planning to snorkel for 30 to 45 minutes. Ten minutes prior to swimming, each participant was directly observed applying a blinded sample of Safe Sea (Nidaria Technology Ltd, Jordan Valley, Israel) to one side of their body and a blinded sample of Coppertone ® (ScheringPlough, Kenilworth, NJ, USA) to the contralateral side as placebo control. Masked 26 g samples of both Safe Sea SPF15 and Coppertone ® SPF15 were provided in identical containers to achieve 2 mg/cm 2 coverage. Sides were randomly chosen by participants. The incidence of jellyfi sh stings was the main outcome measure. This was assessed by participant interview and examination as subjects exited the water. Results. A total of 82 observed water exposures occurred. Thirteen jellyfi sh stings occurred during the study period for a 16% incidence. Eleven jellyfi sh stings occurred with placebo, two with the sting inhibitor, resulting in a relative risk reduction of 82% (95% confi dence interval: 21% -96%; p = 0.02). No seabather ' s eruption or side effects occurred. Conclusions. Safe Sea is a topical barrier cream effective at preventing >80% jellyfi sh stings under real-world conditions.
A n estimated 150 million people worldwide are exposed annually to jellyfi sh. In the United States, over 20% of the population report saltwater recreation annually. In 2002, 48 million Americans swam in salt water, 14.3 million snorkeled, and 4 million scuba dived one or more times. 1 In the United
States, 500,000 jellyfi sh stings are estimated to occur in the Chesapeake Bay and up to 200,000 stings in Florida waters annually. 2 Episodic outbreaks result in mass envenomations and beach closures, as occurred in July 1997 at Waikiki Beach in Hawaii, when more than 800 persons were stung over 2 days. 3 Marine envenomations occur worldwide, and at least 67 deaths have been attributed to the box jellyfi sh alone in the Indo-Pacifi c region. 4, 5 Australia in 2004 reported 19,277 marine stings with an average of 50 hospitalizations annually as a result of severe envenomations. 6 Specifi cally, in Broome, Western Australia, rates of Irukandji syndrome, a severe jellyfi sh envenomation, were 3.3 per 1,000 among the general population from 2001 to 2003. 7 In the Florida Keys,
The abstract was presented at the 9 th CISTM on May 1 to 5, 2005 in Lisbon, Portugal.
J Travel Med 2006; 13: 166-171
three cases of severe envenomation with Irukandji syndrome occurred in 2003. 8 In 2004, a Thai child developed acute renal failure after a jellyfi sh sting. 9 Methods to reduce jellyfi sh envenomations have traditionally relied on mechanical barriers. One common barrier method among surfer and divers includes personal wet suits/stinger suits. However, these suits often leave the face, hands, and feet exposed and are not commonly used by snorkelers or swimmers. A second method is surrounding swimming areas with netting to exclude jellyfi sh. This is common practice at many Australian and Pacifi c island beaches. While these nets may exclude the large box jellyfi sh ( Chironex fl eckeri ) with a bell diameter of 20 to 30 cm, the nets ' 2.5 cm holes allow smaller stinging Irukandji jellyfi sh to enter. In Queensland, Australia, 60% of victims with Irukandji syndrome are stung within the confi nes of stinger nets. 10 Safe Sea ™ is a new, unique jellyfi sh sting inhibitor based on the chemical properties of the mucous coating of clownfi sh (genus: Amphiprion ). Clownfi sh inhabit within the tentacles of sea anemones, which have stinging cells similar to those of jellyfi sh, yet clownfi sh are not stung by the sea anemones. In controlled laboratory environments, the jellyfi sh sting inhibitor, Safe Sea, when applied to volunteers ' arms, prevented 100% of Chrysaora fuscescens stings and 70% of Chiropsalmus quadrumanus stings.
11 Of the C. quadrumanus stings that occurred, their intensity was diminished. 11 The mechanism of Safe Sea ' s sting prevention is multifactorial ( Table 1 ) .
Safe Sea is the fi rst commercially available product utilizing this approach to sting inhibition and is marketed as a " jellyfi sh safe sun block " (Nidaria Technology Ltd, Jordan Valley, Israel). Safe Sea is effective in clinical human laboratory trials but has not been fi eld tested. 11 This is the fi rst fi eld trial of this new jellyfi sh sting inhibitor testing its effi cacy.
Methods
A prospective, double-blind, randomized, placebocontrolled trial occurred investigating the prevention of jellyfi sh stings. Participants intending to snorkel were given blinded 26 g samples of both Safe Sea SPF15 (Nidaria Technology) and Coppertone ® SPF15 (Schering-Plough, Kenilworth, NJ, USA). The lotions ' color and aroma were indistinguishable. Each lotion was provided in identical 30 mL containers colored purple or pink. Assuming an average body surface area of 2.5 m 2 , 52 g of sunscreen complied with the US Food and Drug Administration (FDA) and the European Cosmetic Toiletry and Perfumery Association (COLPA) guidelines for 2 mg/cm 2 of sunscreen application. 12, 13 Each container was to be used completely per application.
Participants applied each lotion to opposite sides of their body 10 minutes prior to swimming. One side (right or left) had Safe Sea, while the opposite had Coppertone applied. The Coppertone side of the body served as a matched placebo control. Sides were randomly chosen by participants. The principal investigator (PI) observed application and recorded to which side of the body each lotion was applied ( Figure 1 ). The products dried prior to water entry. For each water exposure, participants had matched sides of sting inhibitor and control. Participants swam for up to 45 minutes, with the duration recorded. Upon exiting the water, participants were immediately interviewed by the PI as to whether any stings occurred. Stings were self-reported but examined by the PI. Within 15 minutes of leaving the water, participants showered with fresh water. If individuals re-entered the water, the application protocol was repeated. Follow-up physical examination occurred daily during the study period. Participant ' s body hair was quantifi ed on a zero (none), one (light), to two (heavy) scale. Digital photography documented any dermatitis.
Participants and Setting
This study occurred in the Dry Tortugas National Park (NP), 110 km (68 miles) west of Key West, Florida on April 25 to 30, 2004 and in the Sapodilla Cayes, Belize on January 25 to 30, 2005. In the Dry Tortugas NP, the water temperature was 23°C (73°F).
14 In Belize, the water temperature was 27°C (80.5°F). Both sites were chosen due to their popularity with snorkelers and divers and propensity for jellyfi sh during the study periods. Six participants were recruited through direct solicitation for volunteering for each 6-day study period. Two persons volunteered twice (10 total individuals). The exclusion criteria were age <18 years, pregnancy, severe allergy to jellyfi sh, and allergy to any topical 
Sample Size
We selected our sample size by calculating a power of 80% for a signifi cance level of 0.05 with a 75% protection rate for those receiving the sting inhibitor and a 16% sting rate for the placebo group. The sample size was calculated as 72 paired observations. The baseline sting rate of 16% was chosen on the basis of the incidence rate of seabather ' s eruption, caused by the thimble jellyfi sh, in a previous prospective South Florida cohort. 15 The study was powered conservatively for a 75% relative risk reduction of jellyfi sh stings on the basis of the published 85% laboratory protection rate.
11
Randomization Randomization of the sides of the body for lotion application was determined by each participant, and their choice recorded by a masked observer. A priori calculations were designed prior to study initiation for automatic data analysis in case of accidental unmasking during the protocol.
Statistical Analysis
Statistical calculations were performed via SPSS 13.0 (Chicago, IL). Comparisons are expressed as relative risk (RR) with 95% confi dence intervals (CI). Differences between proportions were analyzed by using the two-tailed McNemar ' s test to compare the paired, nominal data of the occurrence of jellyfi sh stings. The relationship between body hair density and jellyfi sh stings was compared with the Kruskal Wallis test. The primary outcome measure is the incidence of jellyfi sh stings. No secondary analyses occurred.
Results
Ten individuals, seven men and three women, participated in a total of 82 paired water exposures. Participants ' average (±SD) age was 29 ± 2 years, weight 74 ± 15 kg, and body surface area 1.9 ± 0.2 m 2 . Eight participants previously had experienced jellyfi sh stings, and four had experienced seabather ' s eruption. Complete follow-up occurred for every person for every exposure. The median duration in the water was 30 minutes (range 25 -45 minutes).
Thirteen jellyfi sh stings were self-reported during the study period with 1.6 ± 3.7 stings per 10 water exposures ( Table 2 ) the placebo resulting in erythema (6 cm diameter on the wrist) and dysesthesias lasting 14 days.
The number needed to treat (NNT ) in this study is nine (95% CI: 5 to 35) to prevent one envenomation. Those with greater amounts of body hair trended toward increased jellyfi sh stings (RR: 3.1; 95% CI: 0.9 -17.9; = 4.2, 2 df, P = 0.15). All stings occurred on extremities in open water.
Cercarial dermatitis (swimmer ' s itch) occurred among six individuals in Belize. No seabather ' s eruption or other adverse skin reactions were reported. Levels of sun tanning did not differ between contralateral sides. Masking was successful through data analysis. After data analysis, inquiry with study participants revealed continued uncertainty as to which lotion was the active treatment, with 40% believing the placebo was the active treatment.
Discussion
The jellyfi sh sting inhibitor, Safe Sea, had an >80% reduction in jellyfi sh stings under real-world conditions during a fi eld trial. The sting inhibitor is designed to keep jellyfi sh nematocysts (stingers) from being activated and is based on the chemical properties of the mucous coating of clownfi sh. Clownfi sh inhabit sea anemones, which have similar stinging nematocysts as jellyfi sh, yet clownfi sh mucous prevents stings by sea anemones. 16 The nematocysts require stimulation by both chemical and tactile stimuli to fi re. 17 -19 Evolutionarily, this makes sense for jellyfi sh or sea anemones not to needlessly discharge their nematocysts against inanimate objects or themselves.
Safe Sea prevents nematocysts from fi ring; however, once the stingers have fi red, Safe Sea is ineffective in blocking or neutralizing the sting itself. The inhibitor is composed not of one single chemical but an amalgamation. The principal of sting prevention is fourfold. First, the inhibitor is highly hydrophobic, convenient for waterproofing, yet this decreases tentacle contact with the skin, increasing the diffi culty of envenomation. 11, 19 Second, the inhibitor contains glycosaminoglycans that mimic the glycosaminoglycans comprising the jellyfi sh ' s bell (ie, body). Because this bell is part of the jelly ' s self-recognition system (thereby preventing it from stinging itself), the inhibitor mimics this self-recognition system to interfere with nematocysts fi ring. Third, the inhibitor contains a competitive antagonist to nonselective chemoreceptors on jellyfi sh. These receptors normally bind amino acids and sugar secretions from prey, sensitizing the nematocysts to enable fi ring thereafter upon mechanical or vibratory stimuli. 18, 20, 21 Finally, calcium and magnesium block transmembrane signaling and reduce the osmotic force within the nematocyst capsule necessary to create the fi ring force. 21 As a fi eld trial, this study was operational and attempted to evaluate the sting inhibitor under realworld conditions. The activities and duration of snorkeling were spontaneous. The IRB deemed it unethical to purposely elicit jellyfi sh stings. Neither restriction nor solicitation of an activity occurred while snorkeling. Thus, this trial should be generalizable to the general population.
Regarding swimmer ' s itch, six individuals had an erythematous, papular, highly pruritic rash on exposed skin with complete sparing under swimwear. The rash ' s distribution was symmetric involving both sides equally. Cercarial dermatitis is caused by nonhuman infecting schistosoma larvae burrowing into the epidermis, and Safe Sea would not be expected to prevent swimmer ' s itch.
The NNT of nine was indicative of the concentration of jellyfi sh in this study. Local, seasonal, and climate factors vary the number and danger of jellyfi sh to ocean goers. Where jellyfi sh are reported by public health authorities or are particularly dangerous, sting inhibitors would be warranted.
Limitations
The ocean exposures in this study were <45 minutes. We did not attempt to determine the effective duration of protection after a single application. Importantly, Safe Sea may have variability in protection against different jellyfi sh species, as both clownfi sh and predators of Cnidaria typically possess species specifi city for their protection. 19 In this study, no Portuguese manof-war were identifi ed by participants. Protection against more venomous jellyfi sh such as the IndoPacifi c box jellyfi sh, Irukandji jellyfi sh, and Portuguese man-of-war would be of great interest. As the sting from a box jellyfi sh carries a mortality rate of 15%, 23 animal studies would fi rst be advisable to prove laboratory effi cacy. A randomized, controlled trial during a high incidence season in a high sting area such as Cairns, Queensland in December or Broome, Western Australia in January would be desirable. 7, 10 This study demonstrates comparable real-world effi cacy in the setting of a fi eld trial to experimental laboratory models.
Conclusions
Safe Sea, a topical jellyfi sh sting inhibitor, is effective at preventing jellyfi sh stings in the setting of a fi eld trial in the Gulf of Mexico and Caribbean. The fi eld effi cacy of the sting inhibitor was similar to the prior laboratory established effi cacy; thus, laboratory studies should be comparable to expected realworld results in the future.
